A Case of CV2/CRMP5-antibody-related Paraneoplastic Optic Neuropathy Associated with Small-cell Lung Cancer

: A 61-year-old woman who had smoked for 40 years developed subacute dizziness, ataxic gait, opsoclonus, and right visual impairment. She had right optic disc swelling and optic nerve gadolinium enhancement on magnetic resonance imaging. She had small-cell lung cancer (SCLC), with CV2/collapsin response mediator protein (CRMP)5 and HuD antibodies in her serum and cerebrospinal fluid. She was diagnosed with paraneoplastic optic neuropathy (PON) accompanied by paraneoplastic opsoclonus-ataxia syndrome. Her symptoms improved after removing the SCLC. Classical PON is rare in Japan. We recommend assaying for CV2/ CRMP5 antibodies and searching for cancer in elderly patients with subacute painless visual impairment.

[1]  M. Motomura,et al.  Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis , 2015, BMJ Open.

[2]  Zhengqi Lu,et al.  Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders , 2014, Neurology.

[3]  A. Kanda,et al.  A case of paraneoplastic optic neuropathy and outer retinitis positive for autoantibodies against collapsin response mediator protein-5, recoverin, and α-enolase , 2014, BMC Ophthalmology.

[4]  E. Rahimy,et al.  Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management. , 2013, Survey of ophthalmology.

[5]  J. Dalmau,et al.  Paraneoplastic neurological syndromes. , 2012, Current opinion in neurology.

[6]  S. Noachtar,et al.  Long term survival in anti-Hu associated adult neuroblastoma , 2009, Journal of the Neurological Sciences.

[7]  J. Honnorat,et al.  Recommended diagnostic criteria for paraneoplastic neurological syndromes , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  J. Parisi,et al.  Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP‐5‐IgG , 2003, Annals of neurology.

[9]  Masami Tanaka,et al.  Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome , 2002, Journal of the Neurological Sciences.

[10]  R. Voltz.  Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy , 2002, The Lancet Neurology.

[11]  E. Benarroch,et al.  CRMP‐5 neuronal autoantibody: Marker of lung cancer and thymoma‐related autoimmunity , 2001, Annals of neurology.

[12]  S. Rauer,et al.  Demonstration of anti-HuD specific oligoclonal bands in the cerebrospinal fluid from patients with paraneoplastic neurological syndromes Qualitative evidence of anti-HuD specific IgG-synthesis in the central nervous system , 2000, Journal of Neuroimmunology.

[13]  J. Honnorat,et al.  Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone , 2000, Journal of neurology, neurosurgery, and psychiatry.

[14]  S. Tsuji,et al.  Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody , 1999, Journal of the Neurological Sciences.

[15]  J. Honnorat,et al.  Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[16]  S. Yoshida,et al.  CRMP-5-IgG in patient with paraneoplastic optic neuritis with lung adenocarcinoma , 2007, Eye.

[17]  D. Damek.  Paraneoplastic retinopathy/ optic neuropathy , 2005, Current treatment options in neurology.

[18]  J. O'fallon,et al.  Immunomodulatory treatment trial for paraneoplastic neurological disorders. , 2004, Neuro-oncology.

[19]  Tohru Inoue,et al.  A case with paraneoplastic optic neuropathy presenting bitemporal hemianopsia , 1991 .